ASPEN PHAR.UN.ADR /1 O.N. (LDZU) — Cash Flow Reinvestment Rate
ASPEN PHAR.UN.ADR /1 O.N. (LDZU) has a Cash Flow Reinvestment Rate of 0.98x as of June 2025, reinvesting €5.05 Billion (capex €5.05 Billion ) from operating cash flow of €5.16 Billion. See LDZU cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
ASPEN PHAR.UN.ADR /1 O.N. Cash Flow Reinvestment Rate (2022–2025)
Historical reinvestment intensity for ASPEN PHAR.UN.ADR /1 O.N. across 4 annual periods. For the full cash flow conversion analysis, see LDZU cash generation efficiency.
Annual Cash Flow Reinvestment Rate for ASPEN PHAR.UN.ADR /1 O.N. (2022–2025)
Year-by-year capital reinvestment analysis for ASPEN PHAR.UN.ADR /1 O.N.. See ASPEN PHAR.UN.ADR /1 O.N. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.98x | €5.05 Billion | €5.16 Billion | €5.05 Billion | ▲ +10.2% |
| 2024 | 0.89x | €5.54 Billion | €6.22 Billion | €5.54 Billion | ▲ +54.3% |
| 2023 | 0.58x | €3.18 Billion | €5.52 Billion | €3.18 Billion | ▲ +11.1% |
| 2022 | 0.52x | €2.79 Billion | €5.37 Billion | €2.70 Billion | — |